Pricing Log in Create free account
Friday 6 November 2026 Export BAX’s income statement to Excel — free account

Baxter International Inc.

BAX Healthcare Medical Instruments & Supplies

Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.

Revenue
+4.97%
EPS
+731.9%
Free cash flow
+255.6%
Total debt
−9.48%

Quarter to September 2026, against a year earlier

25.57 0.93 −3.51%
Market cap
$13.3B
P/E
0.0×
Fwd P/E
21.3×
Dividend yield
0.16%
F-score
4/9
Altman Z
2.12
Beneish M
−2.67
Dividend safety
0/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Baxter International Inc. 10-K filed Feb 12, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:46 PM ET · Document on sec.gov · Filing index

Red flags

  • Impairment

    Baxter International Inc. recorded a goodwill impairment of $485.0 million in fiscal 2025

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 21, 2025: 2 added · 4 removed · 39 modified; 1 with only figures updated

  1. Modified · Company Overview

    Baxter International Inc., through itsour subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products,; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. These products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers and patients at home under physician supervision. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries. As of December 31, 20242025, after giving effect to the recent sale of our Kidney Care business (as discussed below), we manufactured products in over 20 countries and sold them in over 100 countries.